. . . . . . . . "Rapidly and completely absorbed, yielding high and persistent plasma concentrations."@en . . . . . "Nilutamide"@en . "Nilutamide is extensively metabolized andless than 2% of the drug is excreted unchanged in urine after 5 days. Fecal elimination is negligible, ranging from 1.4% to 7% of the dose after 4 to 5 days."@en . . . . . . . . . "Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting."@en . "Nilutamida"@en . . . . "approved"@en . "Humans and other mammals"@en . "# Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12686822 # Lukka H, Waldron T, Klotz L, Winquist E, Trachtenberg J: Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. Curr Oncol. 2006 Jun;13(3):81-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17576447"@en . . . . "Take before breakfast."@en . . . . . . . . . . "Nilutamide"@en . . . . . "For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2)."@en . "Avoid alcohol."@en . . . "Nilandron"@en . "Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration."@en . . . "5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin"@en . " "@en . "63612-50-0"@en . . . . "38.0-59.1 hours"@en . . . . "Nilutamidum"@en . . "Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis."@en . . .